|
gptkbp:instanceOf
|
gptkb:public_company
|
|
gptkbp:acquiredBy
|
gptkb:Talecris_Biotherapeutics
gptkb:Vifor_Pharma
|
|
gptkbp:CEO
|
gptkb:Paul_Perreault
|
|
gptkbp:country
|
gptkb:Australia
|
|
gptkbp:founded
|
1916
|
|
gptkbp:founder
|
gptkb:Government_of_India
|
|
gptkbp:headquarters
|
gptkb:Melbourne,_Australia
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
CSL Limited
|
|
gptkbp:industry
|
gptkb:biotechnology
pharmaceuticals
|
|
gptkbp:ISIN
|
gptkb:AU000000CSL8
|
|
gptkbp:listedOn
|
gptkb:ASX_50
|
|
gptkbp:logo
|
CSL_Limited_logo.svg
|
|
gptkbp:market
|
gptkb:Asia
gptkb:Europe
gptkb:United_States
|
|
gptkbp:marketCap
|
over $100 billion (2023)
|
|
gptkbp:netIncome
|
$2.19 billion (2023)
|
|
gptkbp:notableEvent
|
COVID-19 vaccine manufacturing in Australia
listed on ASX in 1994
production of antivenoms
production of blood plasma products
|
|
gptkbp:notablePerson
|
gptkb:Brian_McNamee_(former_CEO)
Paul Perreault (current CEO)
|
|
gptkbp:notableProduct
|
gptkb:Berinert
gptkb:Fluad
gptkb:Hizentra
gptkb:Privigen
Gardasil (through partnership)
|
|
gptkbp:numberOfEmployees
|
over 30,000
|
|
gptkbp:originalName
|
gptkb:Commonwealth_Serum_Laboratories
|
|
gptkbp:parentCompany
|
none
|
|
gptkbp:privatized
|
1994
|
|
gptkbp:products
|
vaccines
plasma-derived therapies
recombinant proteins
|
|
gptkbp:regulates
|
gptkb:EMA_(Europe)
gptkb:FDA_(USA)
gptkb:Therapeutic_Goods_Administration_(Australia)
|
|
gptkbp:researchInterest
|
immunology
vaccines
hematology
rare diseases
|
|
gptkbp:revenue
|
$13.31 billion (2023)
|
|
gptkbp:servesArea
|
worldwide
|
|
gptkbp:stockExchange
|
gptkb:ASX
|
|
gptkbp:stockSymbol
|
gptkb:CSL
|
|
gptkbp:subsidiary
|
gptkb:CSL_Behring
gptkb:Seqirus
|
|
gptkbp:website
|
https://www.csl.com/
|
|
gptkbp:bfsParent
|
gptkb:CSL
gptkb:NOVN
|
|
gptkbp:bfsLayer
|
5
|